Asset
EFGARTIGIMOD ALFA
argenx SE American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03770403 | phase3 | completed | 2019-03-01 | 2022-06-23 | argenx | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. |
| NCT03334084 | phase1 | completed | 2017-10-11 | 2018-09-19 | argenx | A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects |
| NCT03102593 | phase2 | completed | 2017-03-13 | 2019-04-09 | argenx | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP |
| NCT02965573 | phase2 | completed | 2016-12-30 | 2017-10-20 | argenx | A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness |
| NCT03334058 | phase2 | completed | 2017-10-18 | 2020-10-28 | argenx | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 761195 | BLA | Argenx BV |
Marketed products (1)
- VYVGART